Search

Your search keyword '"Kukreti, Vishal"' showing total 268 results

Search Constraints

Start Over You searched for: Author "Kukreti, Vishal" Remove constraint Author: "Kukreti, Vishal" Database Unpaywall Remove constraint Database: Unpaywall
268 results on '"Kukreti, Vishal"'

Search Results

1. Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP) versus R‐GDP

9. The I-Can Manage web-based cancer self-management program targeting treatment toxicities and health behaviours: Human centred co-design approach and cognitive-think aloud usability testing (Preprint)

10. Human centered co-design and usability testing of a web-based cancer self-management education program (I-Can Manage) targeting treatment toxicities and health behaviours (Preprint)

11. Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

13. Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

14. Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

15. Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

18. Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma

20. Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume

24. Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience

25. Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume

27. Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma

29. Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

32. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis

33. A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma

37. The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma

38. A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score

41. The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database

42. Improving medication reconciliation in ambulatory cancer care.

45. Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

47. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines

48. Evaluation of Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnosis Clinic

49. Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study

50. The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival

Catalog

Books, media, physical & digital resources